A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
Stefania BelloneDana M RoqueEric R SiegelNatalia BuzaPei HuiElena BonazzoliAdele GuglielmiLuca ZammataroNupur NagarkattiSamir ZaidiJungsoo LeeDan-Arin SilasiGloria Shining HuangVaagn AndikyanShari DamastMitchell ClarkMasoud AzodiPeter E SchwartzJoan R Tymon-RosarioJustin A HaroldDennis MauricioBurak ZeybekGulden MenderesGary AltwergerElena RatnerLudmil B AlexandrovAkiko IwasakiYong KongEric SongWeilai DongJulia A ElvinJungmin ChoiAlessandro D SantinPublished in: Cancer (2021)
This study suggests prognostic significance of Lynch-like cancers versus sporadic MSI-H/dMMR ECs for ORR, PFS, and OS when patients are treated with pembrolizumab. Larger confirmatory studies in ECs and other MSI-H/dMMR tumors are necessary. Defective antigen processing/presentation and deranged induction in interferon responses serve as mechanisms of resistance in sporadic MSI-H ECs. Oligoprogression in MSI-H/dMMR patients appears salvageable with surgical resection and/or local treatment and the continuation of pembrolizumab off study. Clinical studies evaluating separate MSI-H/dMMR EC subtypes treated with ICIs are warranted.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- late onset
- prognostic factors
- peritoneal dialysis
- advanced non small cell lung cancer
- dendritic cells
- immune response
- patient reported outcomes
- amyotrophic lateral sclerosis
- case report
- endometrial cancer
- epidermal growth factor receptor
- patient reported